Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D bone shape from CT-scans provides an objective measure of osteoarthritis severity: Data from the IMI-APPROACH study.

Osteoarthritis imaging·2026
Same author

3-dimensional bone shape and knee osteoarthritis: What have we learned?

Osteoarthritis imaging·2026
Same author

Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2026
Same author

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Rheumatology and therapy·2026
Same author

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.

Annals of the rheumatic diseases·2026
Same author

The relationship between real-time ultrasound-detected extra-articular soft tissue pathologies and knee pain in osteoarthritis: a cross-sectional study.

Clinical rheumatology·2026

Related Experiment Video

Updated: Jun 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Predicting outcomes in rheumatoid arthritis.

Philip G Conaghan1

  • 1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. p.conaghan@leeds.ac.uk

Clinical Rheumatology
|January 5, 2011
PubMed
Summary

Predictive models are needed to identify rheumatoid arthritis (RA) patients who will benefit most from costly biologic therapies. Early treatment response can predict long-term outcomes, guiding cost-effective use of RA treatments.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Area of Science:

  • Rheumatology
  • Pharmacoeconomics
  • Biostatistics

Background:

  • Biologic therapies offer improved efficacy for rheumatoid arthritis (RA).
  • High costs can limit the clinical use of biologic therapies.
  • Predictive models are essential for cost-effective biologic use in RA.

Purpose of the Study:

  • To identify patients with RA who have the worst prognosis and will benefit most from biologics.
  • To guide the cost-effective use of modern therapies in RA management.
  • To explore the potential of early treatment response as a predictive factor for long-term outcomes.

Main Methods:

  • Review of studies investigating factors predicting RA onset and progression.
  • Analysis of prognostic factors for guiding aggressive treatment at diagnosis.
  • Evaluation of prediction rules for RA treatment response.
  • Assessment of early treatment response (3 months) as a predictor of 12-month outcomes.

Main Results:

  • Existing prediction rules for RA are often complex or require non-routine biomarkers.
  • Many current prediction models have not significantly impacted clinical practice.
  • Early treatment response (e.g., at 3 months) shows promise in predicting 12-month treatment response in RA patients.

Conclusions:

  • Further research is needed to establish the efficacy of current therapies in preventing RA onset.
  • Long-term cost-effectiveness of targeted biologic treatment in RA requires further investigation.
  • Developing simpler, clinically applicable predictive models for RA is crucial for optimizing biologic therapy use.